Ophthalmologist and Epidemiologist

• Epidemiology in retinoblastoma
• MR imaging and radiogenomics in retinoblastoma
• Molecular genetics of retinoblastoma
• Late effects of retinoblastoma
• Optimisation of quality of care for retinoblastoma patients
• Evaluation of biomarkers for early diagnosis in retinoblastoma
• Second primary tumours (SPTs) in patients with retinoblastoma

Annette Moll is an Ophthalmologist and Professor of Ophthalmology at the Amsterdam UMC. She is program (co-)director of the resident program Ophthalmology. In addition, Moll is co-founder of the Dutch Retinoblastoma Expertise Center and head of the Retinoblastoma Research group.

The Dutch Retinoblastoma Expertise Center (www.retinoblastoom.nl) is a national referral center for multidisciplinary diagnosis, treatment and follow-up of retinoblastoma patients combined with (translational) research. In 2015 and 2021 they obtained recognition as expertise center for rare disease by Dutch Ministry of Health. From 2016 they are part of the Rb European Reference Network. It is the only multidisciplinary center that is actively involved in retinoblastoma care and research in the Netherlands.

Annette Moll has set up or is closely involved in several international projects:

• IRISC in collaboration with NKI, NCI (USA) and worldwide RB centra
• TRANSCEN in collaboration with genetics VUMC, RB clinics Paris and Essen
• Familiar retinoblastoma, DNA mutation, and diagnosis first tumour in eye
• RB-net (rb-net-mdt.org): multidisciplinary team that aims to improve the quality of care of children diagnosed with retinoblastoma at remote and rural areas and support global eye health.
• RB genomic project Paris, Essen, Amsterdam
• CoBioRb project Paris, Essen, Amsterdam

ACTIVITIES

• Co-chair of the European Retinoblastoma Group (EURbG): ERN PaedCan/EuRbG Guidelines - Advanced Unilateral Rb 2022, RB genetics for EURB
• Chair of the Centrale Opleiding Commissie at Amsterdam UMC/VUMC
• Member Registratie Geneeskundige Specialisme (RGS), on behalf of NOG/ Oogheelkunde
• Delegate for the European Board of Ophthalmology ( EBO) and Union Européenne des Médecins Spécialistes, om behalf of NOG & FMS
• Member steering committee of the Program Retinoblastoma Institute Curie/French Society of Ophthalmology
• Member Essen/Germany RB-Registry study
• Board member of the Nelly Reef fund
• Member of the study Evidence levels in pathology for the WHO Classification of Tumours
• Panel of the Unilateral Retinoblastoma Adapted Management Guideline (AMG). St Jude Children ‘s Research Hospital USA
• Co-auteur WHO Classification of Tumours of the Eye, 5th edition (Epidemiology, Clinical Features)
• Clinical Ophthalmic Oncology 4th Edition, Springer - Volume 1, chapter 1
• Contribution at 2023 study book oncology, (chapter 31; Tumoren van de oogleden, ogen en orbita)

Special events

Cycle for retinoblastoma: in 2023 Jan van der Velden cycled 7.000 km from the Netherlands to southern Italy and back to raise money for retinoblastoma research at the Amsterdam UMC. At the end of his journey, Jan raised €15.000 in total (https://www.cycle-for-retinoblastoma.eu/).